BARDA has a proven track record of responding to pandemics and developing lifesaving medical countermeasures. We are rapidly executing new partnerships and building a robust COVID-19 MCM Portfolio because Americans deserve to have safe, effective medical products.
Be the first to get updated on the progress of BARDA Portfolio Partners. Sign-up for our email announcements:
- Rapidly Deployable Capabilities
BARDA JUMP-STARTED COVID-19 TESTS
BARDA scientists started working with private-sector partners in January 2020, days after the novel coronavirus was first reported. BARDA continues to support test development and has expanded support of programs that increase testing speed and capacity for lab tests, as well as broaden access to testing by developing point-of-care and home-use platforms.